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Abstract
Background: AVE9633 is a new immunoconjugate comprising a humanized monoclonal antibody,
anti-CD33 antigen, linked through a disulfide bond to the maytansine derivative DM4, a cytotoxic
agent and potent tubulin inhibitor. It is undergoing a phase I clinical trial. Chemoresistance to anti-
mitotic agents has been shown to be related, in part, to overexpression of ABC proteins. The aim
of the present study was to investigate the potential roles of P-gp, MRP1 and BCRP in cytotoxicity
in AVE9633-induced acute myeloid leukaemia (AML).
Methods: This study used AML cell lines expressing different levels of P-gp, MRP1 or BCRP
proteins and twenty-five samples from AML patients. Expression and functionality of the
transporter protein were analyzed by flow cytometry. The cytotoxicity of the drug was evaluated
by MTT and apoptosis assays.
Results: P-gp activity, but not MRP1 and BCRP, attenuated AVE9633 and DM4 cytotoxicity in
myeloid cell lines. Zosuquidar, a potent specific P-gp inhibitor, restored the sensitivity of cells
expressing P-gp to both AVE9633 and DM4. However, the data from AML patients show that 10/
25 samples of AML cells (40%) were resistant to AVE9633 or DM4 (IC50 > 500 nM), and this was
not related to P-gp activity (p-Value: 0.7). Zosuquidar also failed to re-establish drug sensitivity.
Furthermore, this resistance was not correlated with CD33 expression (p-Value: 0.6) in those cells.
Conclusion: P-gp activity is not a crucial mechanism of chemoresistance to AVE9633. For patients
whose resistance to conventional anthracycline AML regimens is related to ABC protein
expression, a combination with AVE9633 could be beneficial. Other mechanisms such as
microtubule alteration could play an important role in chemoresistance to AVE9633.
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Background
Acute myeloid leukaemia (AML) is characterised by the
proliferation of clonal precursor myeloid cells with
arrested differentiation and subsequent accumulation of
myeloid blasts in the bone marrow. Approximately 60%–
80% of younger adults with AML achieve complete remis-
sion (CR) with conventional chemotherapy such as
cytarabine and an anthracycline. However, a significant
proportion of the responsive patients suffer relapses and
die of treatment-refractory disease. The treatment of
relapsed AML patients is considerably less successful,
especially in the elderly, because the toxicity of standard
induction chemotherapy is poorly tolerated in the older
age group [1,2]. Thus, novel drugs and treatment strate-
gies are major objectives of research; conjugates of anti-
bodies with powerful cytotoxic agents have been
explored. Gemtuzumab ozogamicin (GO) is the first
immunoconjugate approved by the United States Food
and Drug Administration (FDA) for treating refractory
AML [3]. Sanofi Aventis and ImmunoGen have developed
a novel immunoconjugate, AVE9633, which has been
evaluated in Phase I clinical trials on refractory AML
patients.
AVE9633 is an antibody-drug conjugate comprising the
cytotoxic maytansinoid drug DM4 (N2'-deacetyl-N2'-(4-
methyl-4(oxobutyldithio)-1-oxopentyl)-maytansine)
linked via disulfide bonds to the anti-CD33 monoclonal
antibody huMy9-6. CD33 is a transmembrane cell surface
glycoprotein receptor that is specific for myeloid cells. Its
expression is regulated during maturation of the myeloid
lineage, resulting in low level expression on peripheral
granulocytes and tissue macrophages [4]. The CD33 anti-
gen is expressed on approximately 90% of AML myelob-
lasts, including leukaemic clonogenic precursors as well as
normal myeloid precursor cells, but not on CD34+ pluripo-
tent hematopoietic stem cells or in non-haematopoietic tis-
sues [5]. It represents an attractive target for antibody-based
therapy in patients with AML. The immunoconjugate
AVE9633 binds target cells expressing CD33 and is subse-
quently internalised. The DM4 is released within the cell
and exerts its cytotoxic activity. The Phase I clinical trial [6]
has provided evidence that AVE9633 has anti-leukaemia
activity and may be given as an outpatient treatment.
DM4, a structural analogue of maytansine, is a new thiol-
containing and potent maytansinoid. It was synthesized
in order to link maytansinoids to antibodies via disulfide
bonds. Maytansinoids inhibit tubulin polymerization
and microtubule assembly and enhance microtubule
destabilization, so there is potent suppression of microtu-
bule dynamics resulting in a mitotic block and subse-
quent apoptotic cell death [7]. They are approximately
200–1000 times as active as the Vinca alkaloids. Maytan-
sine was evaluated by the National Cancer Institute in
Phase I and II studies during the 1970s [8-12]. Although
complete and partial regressions of several cancers such as
lymphoma, melanoma and acute lymphocytic leukaemia
were noted, severe toxic effects were observed in those
early clinical trials.
Maytansine is a natural product, originally derived from
the Ethiopian shrub Maytansine serrata, so it may be a sub-
strate of ABC proteins. One of the best-characterized
mechanisms of chemoresistance in AML is P-glycoprotein
(P-gp or ABCB1) expression; P-gp serves as an energy-
dependent efflux pump that extrudes chemotherapeutic
agents out of cells [13]. Its expression is particularly high
in older adults and in those with relapsed and refractory
AML and is associated with poor prognosis [14,15]. Other
ABC (ATP-binding-cassette) proteins such as ABCC1
(MRP1), ABCC3 (MRP3) and ABCG2 (BCRP) are also
associated with a poor outcome [16]. Compelling data
from the literature demonstrate that expression of P-gp
and MRP1 attenuates the in vitro cytotoxic activity of the
GO immunoconjugate in AML cells. In addition, inhibi-
tion of P-gp and MRP1 function by CsA, Zosuquidar or
MK-571 restores GO sensitivity [17,18]. It has been dem-
onstrated that P-gp activity in vivo is associated with a
worse prognosis in the clinical response to GO [19].
In this study, we investigated the potential role of P-gp,
MRP1 and BCRP in modulating AVE9633 and DM4 cyto-
toxicity using cell lines specifically expressing those pro-
teins, and also using cells from AML patients. We also
investigated whether Zosuquidar modulates AVE9633
and DM4 cytotoxicity and studied its relationship to P-gp
activity and CD33 expression.
Methods
Cell lines and cell culture
Eight cell lines expressing different levels of three ABC
proteins, P-gp, MRP1 and BCRP, were studied. One series
of cell lines was K562 (human bcr-abl myeloid leukaemia
cells) and its derivatives: K562/HHT40 and K562/HHT90
(developed in our laboratory) [20], and K562/Dox and
K562/BCRP [21] (kindly provided by Y. Sugimoto, Foun-
dation for Cancer Research in Japan). The other cell lines
were HL60, a human myeloid leukaemia cell line, and its
derivatives: HL60/DNR and HL60/ADR (gifted by F.
Lacombe, Bordeaux, France and F. Calvo, Hôpital Saint-
Louis, Paris, France, respectively), which were developed
respectively as Daunorubicin- and Adryamicin-resistant
lines. All the cell lines were cultured in RPMI-1640
medium supplemented with 10% foetal bovine serum, 2
mM glutamine, 50 U/ml penicillin, 50 μg/ml streptomy-
cin, and were incubated at 37°C in a humidified atmos-
phere containing 5% CO2.
AML patient samples
Peripheral blood samples from 25 AML patients were
obtained from cell bank ("Tumorothèque Leucémies"BMC Cancer 2009, 9:199 http://www.biomedcentral.com/1471-2407/9/199
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Hôtel-Dieu N°579). Mononuclear cells (MNC) were iso-
lated using Ficoll-Hypaque density gradients. The fresh
leukaemia cells were cultured under the same general con-
ditions as the cell lines.
Ethical approval
The present study carried out on human blood cells is in
compliance with the Helsinki Declaration, and was
approved by the French Institute National of Cancer
("Tumorothèque Leucémies" Hôtel-Dieu N°579). AML
patient blood samples were obtained after their informed
consent (Formulary EORTC study N°06012).
Drugs and modulators
AVE9633 and DM4 were kindly provided by the Sanofi-
Aventis Research Division (France).
Modulators of ABC proteins were Zosuquidar for P-gp
(Kanisa, USA), MK-571 for MRP1 and Fumitrimorgin C
(FTC) for BCRP (Alexis Biochemicals, USA).
P-gp, MRP and BCRP expression
To detect the extracellular P-gp epitopes, cells (1 × 106)
were incubated for 30 min with phycoerythrin (PE)-con-
jugated UIC2 (Immunotech, France) or phycoerythrin-
conjugated isotype IgG2a as control. To detect the intrac-
ellular epitopes of MRP1 and BCRP, cells (1 × 106) were
first fixed and permeabilized using IntrPrep™ (Beckman
Coulter, Villepinte, France) according to the manufac-
turer's instructions, then incubated with the primary anti-
bodies MRPm6 (MRP1, Monosan, Netherlands) or Bxp21
(BCRP, Immunotech, France) or an isotype control anti-
body (IgG1) for 30 min at room temperature. After one
wash, the cells were incubated with a secondary phyco-
erythrin-conjugated goat anti-mouse IgG (H+L). The fluo-
rescence intensity was measured using a flow cytometer
(EPICS Altra, Beckman Coulter). ABC protein expression
was determined by the ratio of the mean fluorescence
intensity of each specific antibody to the control antibody
(P-gp/IgG2a; MRP1/IgG1, BCRP/IgG1). For each sample,
5,000 events were collected. All the experiments were per-
formed in triplicate.
P-gp, MRP and BCRP activity
P-gp, MRP and BCRP activities were evaluated by the
uptake of their specific fluorescent substrates in the pres-
ence or absence of their specific modulators. Cells (1 ×
106) were incubated respectively with DiOC2(3) (25 nM)
± Zosuquidar (0.3 μM) for P-gp, Calcein-AM (C-AM) (0.2
μM) ± MK571 (5 μM) for MRP or mitoxantrone (3 μM) ±
Fumitremorgin C (FTC) (10 μM) for BCRP for 30 min at
37°C. The samples were then analysed by flow cytometry.
Dye uptake was expressed as a D value ranging from 0 (no
difference) to 1 (no overlap) generated by a Kolmogorov-
Smirnov test, which was used to determine the distribu-
tion of the mean fluorescence intensity (MFI) between the
presence and absence of each modulator. For each sam-
ple, 5,000 events were collected. All the experiments were
performed in triplicate.
Cell viability (MTT assay)
Cells (2 × 104/well for cell lines, 4 × 105/well for patient
cells) were cultured in 96-well plates. Different concentra-
tions of compounds were added in the presence or
absence of Zosuquidar (0.3 μM), MK571 (5 μM) or FTC
(1 μM). After three days' incubation for DM4 and four for
AVE9633, 20 μl of MTT (5 mg/ml, 3-(4,5-dimethyl-2-thi-
azolyl)-2,5-diphenyl-2H-tetrazolium bromide) was
added to each well for a further 4 h incubation. The purple
precipitate was dissolved in 200 μl DMSO and the optical
density was measured using a multiwell plate reader (Mul-
tiskan Ascent, Labsystems). Each condition was repeated
in four wells, and the results are expressed as the means of
the four wells. Viability is expressed as the ratio of the
optical density of the cells in the presence of each drug at
different concentrations with or without modulator and
the control cells in the medium alone. The concentration
effecting 50% inhibition (IC50) was determined by Cal-
cuSyn Software (Biosoft, Cambridge, UK) following the
viability results. All the experiments were performed in
triplicate.
Apoptosis analysis
Cells (106) were stained with AnnexinV-FITC and propid-
ium iodide (PI) in calcium-HEPES buffer for 15 min, as
instructed by the manufacturer (Roche, France). The per-
centage of apoptotic cells was determined by flow cytom-
etry.
Statistical analysis
Statistical discovery software (JMP5.1) was employed,
using Student's t-test for each pair comparison.
Results
P-gp, MRP1 and BCRP expression and activity in human 
leukaemia cell lines
First, we examined the expression and activity of P-gp,
MRP1 and BCRP in the cell lines we used, HL60 and K562
(sensitive) and their variants (resistant). The expression
and activity results are displayed in Table 1. The P-gp,
MRP1 and BCRP protein expression results agreed well
with their activities (r = 0.85, logarithmic). There was no
expression or activity of any of those ABC proteins in the
parental HL60 and K562 cells. However, the resistant cell
lines, K562/HHT40, K562/HHT90 and K562/DOX,
showed marked P-gp expression and activity at different
levels, while MRP1 and BCRP expression and activity were
comparable to those of the parental cell lines. P-gp expres-
sion and activity were increased in those cell lines (Table
1) and was also very high in HL60/DNR cells (Table 1).BMC Cancer 2009, 9:199 http://www.biomedcentral.com/1471-2407/9/199
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HL60/ADR cells showed increased MRP1 expression and
MRP activity, but no expression or activity of the other
proteins (Table 1). K562/BCRP cells specifically showed
BCRP expression and activity, but not the other proteins
(Table 1). It is important to note that no cross-resistance
was observed in these cell lines.
Effect of P-gp activity and its modulator Zosuquidar on 
DM4 and AVE9633 cytotoxicity
To determine the potential role of P-gp protein in DM4
and AVE9633 cytotoxicity, sensitivity to DM4 and
AVE9633 was first examined in the parental cell line HL60
and its variant that specifically expressed P-gp. K562 and
its variant cell lines were only used to test the cytotoxicity
of DM4 because they do not express CD33 antigen. The
IC50 values of DM4 and AVE9633 in those cell lines were
assessed by MTT assays. As illustrated in Table 2, the IC50
values of DM4 in K562/HHT40 (18.4 nM ± 1.2), K562/
HHT90 (36.6 nM ± 2.0), K562/DOX (437.6 nM ± 15.1)
and HL60/DNR (>800 nM) were higher than in the paren-
tal K562 (11.8 nM ± 1.1) and HL60 (14.8 nM ± 0.3) cells.
The increase depended on the activity of P-gp: the more
active the P-gp, the higher the IC50 of DM4 (r = 0.70, log-
arithmic).
The IC50 of AVE9633 in HL60/DNR cells was also above
800 nM, far higher than in the parental HL60 cells (19.9
nM ± 0.7).
We also examined whether Zosuquidar, a specific P-gp
inhibitor, restored the sensitivity to DM4 and AVE9633 in
cells with active P-gp. In the presence of Zosuquidar, the
IC50  values of DM4 in K562/HHT40, K562/HHT90,
K562/DOX and HL60/DNR (Table 2) were respectively
6.5 ± 0.6, 10.1 ± 0.8, 11.6 ± 0.9 and 10.9 ± 0.1 nM, similar
to or less than those in the parental K562 (11.8 ± 1.1) and
HL60 (14.8 ± 0.3) cells. Similar results were also observed
for HL60/DNR with AVE9633 in the presence of Zosuqui-
dar. The IC50 of AVE9633 in HL60/DNR cells was >800
nM without Zosuquidar versus 10.4 ± 2.1 nM with Zosu-
quidar, close to the value observed in HL60 cells.
To confirm that the cytotoxicity of AVE9633 and DM4 was
modulated by overexpression of P-gp, we examined the
induction of apoptosis by these agents in the presence or
absence of Zosuquidar in cells with active P-gp. HL60,
HL60/DNR, K562, K562/HHT40, K562/HHT90 and
K562/Dox cells were treated for 48 or 72 h with DM4 or
AVE9633 alone or in the presence of Zosuquidar, then
stained with Annexin V/PI and analysed by flow cytome-
try. As shown in figure 1, DM4 and AVE9633 alone at 40
nM induced a marked apoptotic response in HL60 cells
(DM4: 59 ± 0.9% and AVE9633: 71.9 ± 2.6%) but not in
the P-gp-functional HL60/DNR cells (DM4:14.7 ± 2.3%
and AVE9633: 18.6 ± 6.8%). However, in the presence of
the P-gp inhibitor Zosuquidar, DM4 and AVE9633 trig-
gered apoptosis significantly in the HL60/DNR cells,
Table 1: P-gp, MRP, BCRP expression and activity in K562, HL60 and their variant cell
Expression Activity
P-gp MRP1 BCRP P-gp MRP BCRP
UIC2 MRPm6 BXP21 DiOC2 (3)/zosuquidar C-AM/MK571 Mitox/FTC
HL60 1.14 ± 0.27 1.2 ± 0.19 1.54 ± 0.79 0 0.09 ± 0.08 0
HL60/DNR 19.30 ± 4.79 0.91 ± 0.52 1.47 ± 0.61 0.98 ± 0.004 0.09 ± 0.04 0
HL60/ADR 1.50 ± 0.44 3.15 ± 0.07 1.56 ± 0.77 0 0.91 ± 0.04 0.17 ± 0.13
K562 0.98 ± 0.17 1.35 ± 0.37 1.25 ± 1.04 0 0.03 ± 0.06 0.043 ± 0.06
K562/HHT40 2.48 ± 0.60 1.53 ± 0.52 1.52 ± 0.51 0.41 ± 0.01 0.17 ± 0.05 0.13 ± 0.14
K562/HHT90 3.24 ± 0.80 1.2 ± 009 1.65 ± 0.64 0.83 ± 0.05 0.22 ± 0.14 0.05 ± 0.07
K562/Dox 11.58 ± 3.42 1.43 ± 0.37 1.85 ± 0.46 0.99 ± 0.01 0.13 ± 0.09 0
K562/BCRP 1.17 ± 0.2 1.13 ± 0.30 7.57 ± 0.54 0 0 0.59 ± 0.11
Table 2: The cytotoxicity of DM4 and AVE9633 in K562, HL60 and their variant cell lines expressing P-gp in the presence or absence of 
the P-gp modulator Zosuquidar
IC50 HL60 HL60/DNR K562 K56/HHT40 K562/HHT90 K562/DOX
AVE9633 (nM) 19.9 ± 0.7 > 800
AVE9633 + Zosuquidar 20.1 ± 1.1 10.4 ± 2.1
DM4 (nM) 14.8 ± 0.3 > 800 11.8 ± 1.1 18.4 ± 1.2 36.6 ± 2.0 437.6 ± 15.1
DM4 + Zosuquidar 18.3 ± 1.3 10.9 ± 0.1 12.6 ± 1.2 6.5 ± 0.6 10.1 ± 0.8 11.6 ± 0.9
* Zosuquidar: 0.3 μMBMC Cancer 2009, 9:199 http://www.biomedcentral.com/1471-2407/9/199
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inducing 75.6 ± 0.6% (DM4) and 88.2 ± 4.4% (AVE9633)
cell death.
The detailed results for K562, K562/HHT40, K562/
HHT90 and K562/Dox are shown in figure 1. We tested
their sensitivity to two concentrations of DM4, 20 nM and
40 nM. The lower concentration (20 nM) is greater than
the IC50 of DM4 in K562/HHT40 cells by the MTT test, but
lower than that in K562/HHT90 cells; 40 nM is greater
than the IC50 in K562/HHT90. We observed that DM4 at
both 20 nM and 40 nM with or without Zosuquidar
induced apoptosis in K562 and K562/HHT40 cells with
similar efficacy, but fewer apoptotic cells were induced in
K562/HHT90 by DM4 at 20 nM (35.4 ± 3.0%), but simi-
lar at 40 nM (47.4 ± 4.9%); this resistance to DM4 at 20
nM was restored by Zosuquidar (48.5 ± 4.8%). DM4
alone at 20 nM and 40 nM did not induce apoptosis in
K562/Dox cells, only 8.1 ± 1.8% and 10.8 ± 2.7% respec-
tively, but in the presence of Zosuquidar the apoptosis
rates were 52.2 ± 8.1% and 62.1 ± 8.0% respectively.
Effect of MRP activity and its modulator MK571 on DM4 
and AVE9633 cytotoxicity
To check the effect of MRP activity on DM4 and AVE9633
cytotoxicity, the viability and apoptosis of HL60 and its
variant MRP+  HL60/ADR cells treated with DM4 or
AVE9633 alone and with MK571 were examined. HL60/
ADR cells were more sensitive to DM4 and AVE9633 than
the parental HL60 cells (Figure 2). The IC50 values of DM4
and AVE9633 in HL60/ADR were even lower than in the
parental cells: 4.3 ± 0.3 and 10.5 ± 0.1 nM for HL60/ADR
versus 16.3 ± 1.9 and 19.9 ± 0.7 for HL60. Addition of the
MRP inhibitor (MK571) to those cells did not change
their sensitivity to DM4 or AVE9633. We next investigated
the induction of apoptosis in HL60 and HL60/ADR cells
by 40 nM DM4 or AVE9633 alone or in the presence of
Apoptosis induced by DM4 and/or AVE9633 in presence or absence of Zosuquidar in HL60, K562 and their variant P-gp  expressing cells Figure 1
Apoptosis induced by DM4 and/or AVE9633 in presence or absence of Zosuquidar in HL60, K562 and their var-
iant P-gp expressing cells. Cells were treated with DM4 or AVE9633 at 20 nM or/and 40 nM in the presence or absence of 
Zosuquidar (0.3 μM) for 48 h, then stained with Annexin V/propidium iodide for flow cytometry. All experiments were done in 
triplicate. A: HL60 (grey) and HL60/DNR (black). B: K562 (blank), K562/HHT40 (stripe), K562/HHT90 (grey) and K562/Dox 
(black).BMC Cancer 2009, 9:199 http://www.biomedcentral.com/1471-2407/9/199
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The sensitivity of HL60 and HL60/ADR cells to DM4 and AVE9633 with or without MRP inhibitor Figure 2
The sensitivity of HL60 and HL60/ADR cells to DM4 and AVE9633 with or without MRP inhibitor. HL60 and 
HL60/ADR cells were treated with AVE9633 (A) or DM4 (B) at different concentrations (3.125, 6.25, 12.5, 25, 50, 100 and 200 
nM) in the presence or absence of MK571 (5 μM) for 72 h, then their viability was measured by an MTT assay. All experiments 
were done in triplicate.
Apoptosis induced by DM4 and AVE9633 in the presence or absence of MRP inhibitor MK571 in HL60 an HL60/ADR cells Figure 3
Apoptosis induced by DM4 and AVE9633 in the presence or absence of MRP inhibitor MK571 in HL60 an 
HL60/ADR cells. HL60 (grey) and HL60/ADR (black) cells were treated with DM4 or AVE9633 at 40 nM in the presence or 
absence of MK571 (5 μM) for 48 h, then stained with Annexin V/propidium iodide for flow cytometry. All experiments were 
done in triplicate.BMC Cancer 2009, 9:199 http://www.biomedcentral.com/1471-2407/9/199
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MK571. The results also showed that the sensitivity of
HL60/ADR cells to DM4 and AVE9633 was similar to that
of the parental HL60 cells (Figure 3). Furthermore,
MK571 (5 μM) failed to enhance the induction of apopto-
sis by DM4 or AVE9633 in HL60/ADR cells: 72.1 ± 6.2%
or 83.3% ± 7.5 without MK571 versus 73.9 ± 6.9% or 72.4
± 8.6% with MK571.
Effect of BCRP activity and its modulator FTC on DM4 and 
AVE9633 cytotoxicity
The effect of BCRP on DM4 cytotoxicity was examined in
K562 and K562/BCRP cells. The viability of K562/BCRP
cells in the presence of DM4 was similar to that of the
parental K562 cells (Figure 4). The BCRP inhibitor (FTC)
did not change the response of those cells to DM4 signif-
icantly (Figure 4). The IC50 values of DM4 alone for K562
and K562/BCRP were respectively 11.8 ± 0.5 and 11.2 ±
1.1, versus 14.2 ± 0.7 and 11.3 ± 0.4 with FTC.
The apoptosis induced in K562/BCRP cells by 40 nM
DM4 alone or in the presence of FTC was comparable to
that of the parental K562 cells (Figure 5). Also, FTC (1
μM) failed to enhance the induction of apoptosis by DM4
in K562/BCRP cells: 73.5 ± 7.8% without FTC versus 68.6
± 4.3% with FTC.
Sensitivity of AML patient cells to AVE9633 and DM4
We next tested the response of fresh cells from AML
patients to DM4 and AVE9633 in order to confirm the
effect of P-gp expression on AVE9633 and DM4 sensitiv-
ity, and to determine whether AVE9633 sensitivity was
associated with CD33 expression in these cells. Thus, the
sensitivity to DM4 and AVE9633, the expression of CD33
and the activity of P-gp were analysed in cells from 25
AML patients. As shown in Additional file 1, cells from 10
(40%) of the patients were highly resistant to AVE9633
or/and DM4; the IC50 of AVE9633 or DM4 was above 500
nM, the maximum concentration used in vitro, or above
200 nM for one patient's cells (there was a lack of concen-
trated AVE9633). At 200 nM, the viability of this patient's
cells was about 95%. AVE9633-resistant cells from the
patients were also resistant to DM4. Among the 10 non-
responding patients, only three (12%) had cells with weak
P-gp activity (P8, P12 and P17; D = 0.21, 0.24 and 0.26).
Furthermore, pre-incubation of the cells with Zosuquidar
did not restore the cytotoxicity of either AVE9633 or DM4.
Interestingly, among the 15 responders (60%), the sensi-
tivity to AVE9633 or DM4 in cells from three patients
(12%) was enhanced by Zosuquidar (see Additional file
1); the cells from all three of these patients showed active
P-gp (P16, P24 and P6; D = 0.25, 0.27 and 0.38). This
result demonstrates that P-gp activity is not associated
with AVE9633 and/or DM4 resistance (p-value: 0.7), and
is not crucial for such resistance. This resistance to
AVE9633 in vitro was not associated with CD33 expres-
sion in any patient (p-value: 0.6), nor was the sensitivity
to AVE9633 among the responder patient cells.
We also compared the activity of AVE9633 to that of GO
in 21 of the 25 patients in the presence or absence of
Zosuquidar (see Additional file 1). Among 10 patients
who were highly resistant to AVE9633 or/and DM4, the
cells from eight were examined for GO response: the cells
from four were sensitive to GO and those from the other
four were insensitive. Among 15 patients who were sensi-
tive to AVE9633 or/and DM4, the cells from 13 were
examined for GO response; those from 10 were sensitive
and those from the other three were resistant. Zosuquidar
enhanced the cytotoxicity of GO in P-gp active cells from
P16 and P6. This effect was more marked for GO than for
AVE9633. However, Zosuquidar did not change the resist-
ance status of P9.
Discussion
P-gp, MRP1, MRP3 and BCRP activities have been shown
to contribute to resistance to conventional cytarabine and
anthracycline-based chemotherapy such as Daunoru-
bicin, Idarubicin and Mitoxantrone in AML [13]. P-gp and
MRP1 have also been associated with attenuated GO-
induced cytotoxicity in AML cells. To determine whether
P-gp, MRP1 and BCRP affect the cytotoxic response to
The sensitivity of K562 and K562/BCRP cells to DM4 with or  without BCRP inhibitor Figure 4
The sensitivity of K562 and K562/BCRP cells to DM4 
with or without BCRP inhibitor. K562 and K562/BCRP 
cells were treated with DM4 at different concentrations 
(3.125, 6.25, 12.5, 25, 50, 100 and 200 nM) in the presence 
or absence of FTC (1 μM) for 72 h, and then their sensitivity 
was measured by an MTT assay. All experiments were done 
in triplicate.
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AVE9633 and DM4, different cell lines specifically
expressing P-gp, MRP1 and BCRP were used. Our data
demonstrate that MRP1 and BCRP did not affect
AVE9633- and/or DM4-induced cytotoxicity in HL60/
ADR and K562/BCRP cells, which respectively express
MRP and BCRP, compared to the parental HL60 and K562
cells. The MRP and BCRP inhibitors, MK571 and FTC,
failed to enhance cytotoxicity in these MRP- and BCRP-
positive cells. We also showed that P-gp function attenu-
ated AVE9633- and/or DM4-induced cytotoxicity in
HL60/DNR, K562/HHT40, K562/HHT90 and K562/Dox
cells, and that Zosuquidar restored their sensitivity. How-
ever, it seems that we cannot extrapolate these findings
from AML cell lines to the clinical setting, because P-gp
activity in HL60/DNR, K562/HHT40, K562/HHT90 and
K562/DOX cells showed D values of 0.98 ± 0.004, 0.41 ±
0.01, 0.83 ± 0.05 and 0.99 ± 0.01 respectively, which are
far higher than those observed in the AML patient cells.
Furthermore, the plasma levels obtained in the AVE9633
clinical trials with doses ranging between 15 mg/m2 and
260 mg/m2 were 7–119 μg/ml (46 – 783 nM), which is
much higher than the IC50 obtained in the cell lines.
Sensitivity to AVE9633 or DM4 was examined in samples
of cells from 25 AML patients. The doses of AVE9633 or
DM4 tested were from 1.5 nM to 500 nM (76 μg/ml),
which is in line with the plasma concentration of 69 μg/
ml observed in patients undergoing AVE9633 therapy at a
dose of 150 mg/m2 [6]. Among the AML patients tested,
the cells from 10 (40%) were non-responsive to AVE9633
and/or DM4 and did not exhibit high P-gp activity; cells
from only three patients had moderate P-gp activity
(D>0.2, but D<0.3). Among 15 (60%) responsive cell
samples, those from two patients showed high P-gp activ-
ity (D> 0.3), and those from four patients showed weak P-
gp activity (D>0.2, but <0.3). These results suggest that P-
gp activity does not play a pivotal role in chemoresistance
to AVE9633 or DM4.
The patient cells that were resistant to AVE9633 were also
resistant to DM4, and resistance was not related to CD33
expression. This suggests that other chemoresistance
mechanisms are involved in AVE9633- or DM4-induced
cytotoxicity. DM4, an antimitotic agent like other Vinca
alkaloids, binds preferentially to α/β-tubulin heterodim-
ers and inhibits tubulin polymerization and microtubule
assembly, increasing microtubule destabilization, which
leads to a potent suppression of microtubule dynamics
and results in mitotic block and subsequent apoptotic cell
death [7]. The balance between polymerized and non-
polymerized tubulin is an important determinant of the
response to Vinca alkaloid-based chemotherapy regimens
in childhood ALL [22]. Clinical evidence shows that βIII-
tubulin expression is involved in the resistance to taxanes
Apoptosis induced by DM4 in the presence or absence of BCRP inhibitor FTC in K562 and K562/BCRP cells Figure 5
Apoptosis induced by DM4 in the presence or absence of BCRP inhibitor FTC in K562 and K562/BCRP cells. 
K562 (grey) and K562/BCRP (black) cells were treated with DM4 at 40 nM in the presence or absence of FTC (1 μM) for 48 h, 
and then stained with Annexin V/propidium iodide for flow cytometry. All experiments were done in triplicate.BMC Cancer 2009, 9:199 http://www.biomedcentral.com/1471-2407/9/199
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and Vinca alkaloids in lung [23-25], breast [26,27] and
ovarian cancers [28,29]. In addition, βIII-tubulin siRNA
sensitizes cancer cells to tubulin-binding chemotherapeu-
tic drugs [30]. This offers a rationale for investigating the
involvement of different subtypes of tubulin in resistance
to AVE9633/DM4, and for studying the benefit of
AVE9633 in combination with the conventional anthracy-
cline AML regimens, resistance to which is related to the
expression of ABC proteins.
Conclusion
P-gp activity, but not MRP1 and BCRP, attenuated
AVE9633 and DM4 cytotoxicity in myeloid cell lines.
Zosuquidar, a potent specific P-gp inhibitor, restored the
sensitivity of those cells expressing P-gp to both AVE9633
and DM4. However, P-gp activity is not a crucial mecha-
nism of chemoresistance to AVE9633 in AML patient cells,
in contrast to the Gemtuzumab ozogamicin (GO) immu-
noconjugate. AVE9633 may be a potent cytotoxic chemo-
therapy for AML patients whose blasts express P-gp,
especially older patients, and it may be beneficial in com-
bination with the conventional anthracycline AML regi-
mens, resistance to which is related to the expression of
ABC proteins. Other mechanisms such as microtubule
alteration could play an important role in chemoresist-
ance to AVE9633.
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